<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813460</url>
  </required_header>
  <id_info>
    <org_study_id>CR108168</org_study_id>
    <secondary_id>64041575RSV1004</secondary_id>
    <secondary_id>2016-001517-24</secondary_id>
    <nct_id>NCT02813460</nct_id>
  </id_info>
  <brief_title>Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Double-blind, Randomized Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate in a double-blinded fashion the taste and overall
      acceptability profile of different ALS-008176 oral liquid formulations as compared to the
      reference formulation (ALS-008176: 60 milligram per milliliters (mg/mL) oral suspension
      without sweetener/flavor) for pediatric clinical development and commercialization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate in a Double-Blinded Fashion the Taste and Overall Acceptability Profile of Different ALS-008176 Oral Liquid Formulations as Compared to the Reference Formulation (ALS-008176: 60 mg/mL Oral Suspension Without Sweetener/Flavor)</measure>
    <time_frame>Up to 2 hours of study drug administration</time_frame>
    <description>Taste will be assessed using a questionnaire designed for the purpose. The questionnaire will consist of a visual analogue scale to rate 5 items (sweetness, bitterness, aroma type, aroma strength, and smell) as well as overall acceptability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events and serious adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation A (ALS-008176)</intervention_name>
    <description>Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation B (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation C (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation D (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation E (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation F (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.</description>
    <arm_group_label>Session 1: Sequence 1</arm_group_label>
    <arm_group_label>Session 1: Sequence 2</arm_group_label>
    <arm_group_label>Session 1: Sequence 3</arm_group_label>
    <arm_group_label>Session 1: Sequence 4</arm_group_label>
    <arm_group_label>Session 1: Sequence 5</arm_group_label>
    <arm_group_label>Session 1: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation G1 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation G2 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation G3 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation H1 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation H2 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formulation H3 (ALS-008176)</intervention_name>
    <description>60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.</description>
    <arm_group_label>Session 2: Sequence 1</arm_group_label>
    <arm_group_label>Session 2: Sequence 2</arm_group_label>
    <arm_group_label>Session 2: Sequence 3</arm_group_label>
    <arm_group_label>Session 2: Sequence 4</arm_group_label>
    <arm_group_label>Session 2: Sequence 5</arm_group_label>
    <arm_group_label>Session 2: Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be a man or woman between 18 and 65 years of age, inclusive, at
             Screening

          -  Participant must sign an informed consent form (ICF) indicating that he or she
             understands the purpose of, and procedures required for, the study and is willing to
             participate in the study

          -  Participant must be willing and able to adhere to the prohibitions and restrictions
             specified in this protocol

          -  A female participant must be of non-childbearing potential, defined as either: 1)
             Postmenopausal; 2) A postmenopausal state is defined as no menses for at least 12
             months without an alternative medical cause and a serum follicle stimulating hormone
             (FSH) level in the postmenopausal range (more than [&gt;] 40 international units per
             liter [IU/L] or milli international units per milliliters [mIU/mL]), or 3) Permanently
             sterile; 4) Permanent sterilization methods include hysterectomy, bilateral
             salpingectomy, bilateral tubal occlusion/ligation procedures (without reversal
             operation), and bilateral oophorectomy

          -  During the study and for a minimum of one spermatogenesis cycle (defined as
             approximately 90 days) after receiving the (last dose of) study drug, a male
             participant 1) who is sexually active with a woman of childbearing potential must
             agree to use a barrier method of contraception (example, condom with spermicidal
             foam/gel/film/cream/suppository); 2) who is sexually active with a pregnant woman must
             use a condom; 3) must agree not to donate sperm

          -  Female partners of male participants must either be surgically sterilized,
             postmenopausal or, if of childbearing potential, must agree to use at least one of the
             following contraceptive methods for 90 days following the final dose of study drug: a
             nonhormonal intrauterine device with spermicide; contraceptive sponge with spermicide,
             diaphragm with spermicide, cervical cap with spermicide, or oral, implantable,
             transdermal, or injectable-hormonal contraceptives

          -  A female participant must have a negative serum beta human chorionic gonadotropin
             (beta hCG) pregnancy test at Screening and a negative urine pregnancy test at Day 1
             predose

          -  A female participant must agree not to donate eggs during the study and for at least
             90 days after receiving the (last dose of) study drug

          -  Participant must have a body mass index; weight (kilogram per height square
             [kg/height^2 [m^2]) between 18.0 and 30.0 kilogram per meter square
             (kg/m^2)(inclusive) at Screening

          -  Participant must be non-smokers and/or have not used chewing tobacco for at least 3
             months prior to Screening

          -  Participant must be able to taste and smell normally, to their own opinion, at all
             times throughout the study duration. Participants who have an impaired sense of taste
             and/or smell due to any conditions such as allergic rhinitis, common cold or sinusitis
             are not eligible to take part in or to continue the study

          -  Participant must be able to read and write

        Exclusion Criteria:

          -  Participant has a mouth pathology including, but not limited to, pain, ulcer, edema,
             mucosal erosion, gingivitis and/or (dental) abscesses, or receives treatment for oral
             pathologies or oral treatment for any disease

          -  Participant has a history of current clinically significant medical illness including
             Sjogren's syndrome, cardiac arrhythmias or other cardiac disease, pernicious anemia,
             hematologic disease, coagulation disorders, lipid abnormalities, significant pulmonary
             disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or
             renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or
             any other illness that the Investigator considers should exclude the participant or
             that could interfere with the interpretation of the study results

          -  Participant with a history of clinically significant drug allergy such as, but not
             limited to, sulfonamides and penicillins, or drug allergy diagnosed in previous
             studies with experimental drugs

          -  Participant with presence of any febrile illness or symptoms of upper or lower
             respiratory tract infection in the 14 days before the (first) dose of study drugs

          -  Participant has a history of drug or alcohol abuse according to Diagnostic and
             Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 5 years
             before screening or positive test result(s) for alcohol and/or drugs of abuse
             (including barbiturates, opiates, cocaine, amphetamines, methadone, benzodiazepines,
             methamphetamine, tetrahydrocannabinol, phencyclidine, and tricyclic antidepressants)
             at Screening

          -  Participant has known allergies, hypersensitivity, or intolerance to ALS-008176 or its
             excipients

          -  Participant has received an investigational drug (including investigational vaccines)
             or used an invasive investigational medical device within 90 days before the planned
             first dose of study drug

          -  Participant is a man who plans to father a child while enrolled in this study or
             within 90 days after the last dose of study drug, or who is unwilling to use
             acceptable methods of contraception

          -  Vulnerable participant (example, incarcerated individuals)

          -  Participant is an employee of the Investigator or study site, with direct involvement
             in the proposed study or other studies under the direction of that Investigator or
             study site, as well as family members of the employees or the Investigator or
             participant is an employee of Johnson &amp; Johnson

          -  Participant has any condition for which, in the opinion of the Investigator,
             participation would not be in the best interest of the participant (example,
             compromise the well-being) or that could prevent, limit, or confound the
             protocol-specified assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

